8Telecom weighs transfer of listing status to South Korean health product company
TELECOM infrastructure group 8Telecom International Holdings' listing status could be transferred to a South Korean health product company, its judicial managers told the Singapore Exchange on Friday.
8Telecom has inked a memorandum of understanding with South Korea-listed stainless steel product maker Kossen Co, which controls BiogenicsKorea Co with an interest of 40.2 per cent.
Tardis Capital (Singapore) Pte Ltd, a boutique mergers and acquisition advisory firm, introduced the parties in the transaction and will be advising Kossen and BiogenicsKorea.
While the memorandum of understanding is not legally binding, it comes with a provision requiring both parties to commit to exclusive negotiations, for at least 30 days, on a definitive agreement for the proposed restructuring of 8Telecom.
Still, judicial managers Andrew Grimmett and Lim Loo Khoon, of Deloitte & Touche, warned: "There is no certainty or assurance that the definitive agreement will be entered into at this juncture, and if entered into, whether the transactions contemplated therein can or will proceed."
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
BlackRock, Citadel reap billion-dollar deals from Australia fund
Credit Suisse faces 50 billion won South Korea short-sale fine
Nvidia supplier SK Hynix says HBM chips almost sold out for 2025
Jim Beam owner bets on canned vodka cocktails to double revenue
Hot stock: Nio climbs about 19.8% on stronger vehicle delivery performance
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO